What is Pacira BioSciences, Inc.'s EBITDA margin?

Pacira BioSciences, Inc. (PCRX) reported EBITDA margin of 15.7% in Q1 2026.

What is the long-term trend for Pacira BioSciences, Inc.'s EBITDA margin?

Over 3 years (2020 to 2025), Pacira BioSciences, Inc.'s EBITDA margin has grown at a -0.5% compound annual growth rate (CAGR), from 15.4% to 15.2%.

What does EBITDA margin mean?

EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.

Pacira BioSciences, Inc. PCRX EBITDA margin

EBITDA margin at other companies

Avanos MedicalAVNS

-3.6%-1.7pp

Collegium Pharmaceutical, Inc.COLL

31.1%-18.9pp

AtriCureATRC

-1.2%-0.5pp

Other financials

Income statement

See full

Revenue$177.4M+5.0%

Gross profit$141.0M+4.7%

Operating income$6.9M+247%

Net income$2.9M-39.4%

EPS (diluted)$0.07-30.0%

Balance sheet

See full

Cash & equivalents$144.3M-49.1%

Total debt$411.2M+15.3%

Total equity$653.9M-18.1%

Total assets$1.2B-23.8%

Cash flow

See full

Operating cash flow$25.7M-27.6%

CapEx$2.7M-68.1%

Free cash flow$23.0M-14.7%

Valuation

See full

Market cap$942.78M-16.0%

Enterprise value$1.21B+1.2%

P/E183.5×—

P/S1.3×-0.3×

Profitability

See full

Gross margin79.3%+1.7pp

Operating margin3.3%—

Net margin0.7%—

FCF margin18.1%-4.6pp

Returns & leverage

See full

Return on equity0.7%—

Debt / equity0.6×+0.2×

Current ratio4.7×+2.3×

Where this comes from

Calculated from Pacira BioSciences, Inc.’s reported figures.

ebitda/total revenue=15.7%

Based on trailing twelve months.

The official record: Pacira BioSciences, Inc.’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pacira BioSciences, Inc.'s ebitda margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Pacira BioSciences, Inc.'s EBITDA margin?: Pacira BioSciences, Inc. (PCRX) reported EBITDA margin of 15.7% in Q1 2026.
What is the long-term trend for Pacira BioSciences, Inc.'s EBITDA margin?: Over 3 years (2020 to 2025), Pacira BioSciences, Inc.'s EBITDA margin has grown at a -0.5% compound annual growth rate (CAGR), from 15.4% to 15.2%.
What does EBITDA margin mean?: EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.